Clinician-guided care in Westlake, Ohio
Peptide options, explained with clarity.
ASR offers only FDA-approved peptide medications. Additional peptides in this directory are shown for information only; ASR does not offer or prescribe them.
Two clear categories
Understand what ASR offers and what is information only.
FDA approval applies to a specific product, formulation, route, and labeled indication. The first group covers peptides with FDA-approved products; the second group is educational content about peptides ASR does not offer.
Peptides with FDA-Approved Products
ASR offers only FDA-approved products from this group when clinically appropriate and available. A listed ingredient does not mean every brand or indication is offered.
Additional Peptides - Information Only
These peptides are described for information only. ASR does not offer or prescribe them. FDA status, evidence limits, and safety concerns are stated plainly.
Peptide directory
Explore approved product options and information-only topics.
ASR offers only FDA-approved peptide medications. Additional peptides are for information only and are not offered or prescribed.
27 peptide topics shown
Semaglutide
FDA-approved semaglutide products include Ozempic, Rybelsus, and Wegovy, each with specific labeled uses. ASR discusses the exact FDA-approved product and its availability during consultation.
Tirzepatide
FDA-approved tirzepatide products include Mounjaro and Zepbound, each with specific labeled uses. ASR discusses the exact FDA-approved product and its availability during consultation.
Tesamorelin
FDA approval belongs to Egrifta products and their specific labeled indication. ASR discusses only FDA-approved products when clinically appropriate and available.
Bremelanotide / PT-141
Vyleesi is an FDA-approved bremelanotide product with a narrow labeled indication. ASR discusses only the approved product when clinically appropriate and available.
Elamipretide / SSR-31
Forzinity is FDA-approved for qualifying patients with Barth syndrome. ASR discusses only the approved product when clinically appropriate and available.
Sermorelin
Previously approved Geref products are discontinued. Sermorelin is included here for information only and is not offered by ASR.
AOD-9604
No FDA-approved counterpart was identified. FDA has cited inadequate safety information and potential significant risks for compounded use.
BPC-157
No FDA-approved counterpart was identified. FDA has cited limited safety information and potential immunogenicity and characterization risks.
CJC-1295
No FDA-approved counterpart was identified. FDA reports limited clinical data and serious adverse events associated with CJC-1295.
CJC-1295 + Ipamorelin
No FDA-approved combination product was identified. The compounded combination is not FDA-approved, and both components require careful risk review.
DSIP / Emideltide
No FDA-approved counterpart was identified. FDA states that it lacks sufficient safety information for compounded emideltide.
Epitalon
No FDA-approved counterpart was identified. Human safety information is limited, so longevity claims require careful qualification.
GHK-Cu
No FDA-approved injectable counterpart was identified. Injectable use should not be confused with topical cosmetic products.
GHRP-2
No FDA-approved counterpart was identified. FDA has identified potential significant safety risks for injectable and nasal compounded use.
GHRP-6
No FDA-approved counterpart was identified. FDA has identified potential significant safety risks for compounded use.
Ipamorelin
No FDA-approved counterpart was identified. FDA has cited immunogenicity, impurity, and serious-adverse-event concerns.
Kisspeptin
No FDA-approved counterpart was identified for the clinic product. The exact peptide form and route must be reviewed during consultation.
KPV
No FDA-approved counterpart was identified. FDA states that it has not identified human exposure data for KPV drug products.
LL-37 / Cathelicidin
No FDA-approved counterpart was identified. FDA reports insufficient safety information and concerning nonclinical findings.
Melanotan II
No FDA-approved counterpart was identified. FDA cites published serious-adverse-event reports and other safety concerns.
MOTS-C
No FDA-approved counterpart was identified. FDA states that it has not identified human exposure data for MOTS-C drug products.
PEG-MGF
No FDA-approved counterpart was identified. FDA states that it has not identified human exposure data for PEG-MGF drug products.
Retatrutide
Retatrutide is investigational and is not FDA-approved. This page is for information only; ASR does not offer or prescribe it.
Selank
No FDA-approved counterpart was identified. FDA has cited immunogenicity and peptide-impurity concerns and inadequate human safety information.
Semax
No FDA-approved counterpart was identified. FDA has cited immunogenicity and peptide-impurity concerns and inadequate safety information.
TB-500
No FDA-approved counterpart was identified. FDA reports a lack of identified human exposure data and potential safety risks.
Thymosin Alpha-1
No U.S. FDA-approved counterpart was identified. FDA states that available safety information is inadequate for compounded thymosin alpha-1.
Important medication notice
A consultation determines what is appropriate - not a webpage.
ASR offers only FDA-approved peptide medications. A clinician reviews the exact approved product, labeled use, alternatives, risks, and suitability before prescribing. The additional peptides described here are for information only and are not offered by ASR.
Personalized medical consultation
Bring your goals. Leave with a clearer understanding of your options.
Your provider will review your health history, the exact FDA-approved product, its indication, possible benefits, limitations, alternatives, and risks before recommending care.